Physician profile
Wing-Kin Syn
NPI 1487023057
$43,470.57
in general payments reported to CMS, 2019-2025
13 companies · $24K in 2025
The $24K reported for 2025 was more than what 95% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,120 · 2020: $1,515 · 2021: $2,450 · 2022: $64.53 · 2023: $326 · 2024: $12K · 2025: $24K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $22K · Consulting Fee: $11K · Travel and Lodging: $1,738 · Food and Beverage: $1,424.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $21,959.88 |
| Consulting Fee | $11,200.00 |
| Travel and Lodging | $1,737.51 |
| Food and Beverage | $1,423.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $13,671.07 | 2022-2025 | Wegovy |
| Ipsen Biopharmaceuticals, INC | $8,940.03 | 2024-2025 | Bylvay |
| Merck Sharp & Dohme LLC | $8,105.51 | 2024 | |
| Mirum Pharmaceuticals, INC. | $5,100.00 | 2025 | Livmarli |
| Intercept Pharmaceuticals, INC. | $3,219.47 | 2019-2023 | Ocaliva |
| Theratechnologies INC. | $2,000.00 | 2021 | |
| Echosens North America, INC. | $1,573.26 | 2020-2024 | Fibroscan |
| Medtronic, INC. | $450.00 | 2021 | |
| Boston Scientific Corporation | $192.99 | 2023-2024 | Spyglass, Apollo Esg Nxt System, Apollo Esg System |
| Madrigal Pharmaceuticals | $83.44 | 2025 | Rezdiffra |
| Gilead Sciences, INC. | $57.11 | 2023 | |
| Mallinckrodt Hospital Products INC. | $47.13 | 2023 | Terlivaz |
| Abbvie INC. | $30.56 | 2023 | Rinvoq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wing-Kin Syn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.